The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding (Q31869703)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

1 reference

based on heuristic

inferred from title

hypertriglyceridemia

1 reference

based on heuristic

inferred from title

author name string

de Man FH

1

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

de Beer F

2

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

van der Laarse A

3

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Jansen H

4

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Leuven JA

5

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Souverijn JH

6

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Vroom TF

7

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Schoormans SC

8

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Fruchart JC

9

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Havekes LM

10

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Smelt AH

11

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

153

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

363-371

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Transport of Very Low Density Lipoprotein Triglycerides in Varying Degrees of Obesity and Hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Plasma glucose and insulin responses to oral glucose in nonobese subjects and patients with endogenous hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Separation of plasma lipoproteins by density-gradient ultracentrifugation

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

Plasma triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900409-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0021-9150(00)00409-3

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31869703&oldid=1910668820"